Results 51 to 60 of about 1,302,226 (351)
Reducing dementia risk by targeting modifiable risk factors in mid-life: study protocol for the Innovative midlife intervention for dementia deterrence (In-MINDD) randomised controlled feasibility trial [PDF]
, 2015 Background Dementia prevalence is increasing as populations live longer, with no cure and the costs of caring exceeding many other conditions. There is increasing evidence for modifiable risk factors which, if addressed in mid-life, can reduce the risk ...
Alex McConnachie +13 more
core +1 more source
Alzheimer's & Dementia, 2021 At present, there is limited data on the risks, disparity, and outcomes for COVID‐19 in patients with dementia in the United States.
QuanQiu Wang +3 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef +10 more
wiley +1 more source
Effect of therapeutic massage on pain in patients with dementia [PDF]
, 2016 Introduction The aim was to investigate whether therapeutic massage was effective in relieving pain in elderly residents with dementia. Methods A randomized controlled study was conducted in an aged care facility.
Kapoor, Yamini, Orr, Robin
core +1 more source
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Alzheimer's & Dementia, 2020 WethankDrs. Di Lorenzo andKoch for sharing their interest and views regarding our recent report on in vivo measurement of synaptic loss in Alzheimer’s disease (AD) using positron emission tomography (PET) to quantify [11C]UCB-J binding to synaptic ...
A. Mecca, Christopher H. Dyck
semanticscholar +1 more source
Dementia & Neuropsychologia, 2022 There is currently no cure for neurodegenerative or vascular dementias, but some pharmacological and non-pharmacological interventions may contribute to alleviate symptoms, slow disease progression and improve quality of life.
Paulo Caramelli +17 more
semanticscholar +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT C‐truncating variants in the charged multivesicular body protein 2B (CHMP2B) gene are a rare cause of frontotemporal lobar degeneration (FTLD), previously identified only in Denmark, Belgium, and China. We report a novel CHMP2B splice‐site variant (c.35‐1G>A) associated with familial FTLD in Spain. The cases were two monozygotic male twins who
Sara Rubio‐Guerra +17 more
wiley +1 more source
Diagnosis and Management of Dementia: Review.
Journal of the American Medical Association (JAMA), 2019 Importance Worldwide, 47 million people live with dementia and, by 2050, the number is expected to increase to 131 million. Observations Dementia is an acquired loss of cognition in multiple cognitive domains sufficiently severe to affect social or ...
Z. Arvanitakis, R. Shah, D. Bennett
semanticscholar +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Reliable biomarkers are essential for tracking disease progression and advancing treatments for multiple system atrophy (MSA). In this study, we propose the MSA Atrophy Index (MSA‐AI), a novel composite volumetric measure to distinguish MSA from related disorders and monitor disease progression. Methods Seventeen participants with an
Paula Trujillo +11 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The cervical spinal cord (cSC) is highly relevant to clinical dysfunction in multiple sclerosis (MS) but remains understudied using quantitative magnetic resonance imaging (MRI). We assessed magnetization transfer ratio (MTR), a semi‐quantitative MRI measure sensitive to MS‐related tissue microstructural changes, in the cSC and its ...
Lisa Eunyoung Lee +26 more
wiley +1 more source